Board Meeting Details

The Board of Directors meeting was held on November 04, 2026, commencing at 6:30 PM and concluding at 8:30 PM. The meeting approved:

1. Unaudited Financial Results (Consolidated and Standalone) for quarter and half year ended September 30, 2026

2. Reviewed other business of the company

Key Financial Performance - Standalone (All amounts in ₹ Lakhs)

Quarterly Performance (Q2 FY2026):

  • Revenue from Operations: ₹4,220.38 (vs ₹587.74 in Q2 FY2025 - 618% increase)
  • Other Income: ₹57.20 (vs ₹171.26 in Q2 FY2025)
  • Total Income: ₹4,477.58 (vs ₹759.00 in Q2 FY2025 - 490% increase)
  • Profit Before Tax: ₹2,112.85 (vs ₹19.84 in Q2 FY2025)
  • Current Tax: ₹538.39 (vs ₹0 in Q2 FY2025)
  • Net Profit: ₹1,601.20 (vs ₹237.81 in Q2 FY2025 - 573% increase)
  • Basic EPS: ₹0.36 (vs ₹0.05 in Q2 FY2025)
  • Diluted EPS: ₹0.36 (vs ₹0.05 in Q2 FY2025)

Half-Yearly Performance (H1 FY2026):

  • Revenue from Operations: ₹6,772.61 (vs ₹1,126.85 in H1 FY2025)
  • Total Income: ₹6,883.78 (vs ₹1,409.08 in H1 FY2025)
  • Profit Before Tax: ₹4,137.08 (vs ₹157.16 in H1 FY2025)
  • Net Profit: ₹3,104.18 (vs ₹340.77 in H1 FY2025)
  • Basic EPS: ₹0.71 (vs ₹0.08 in H1 FY2025)
  • Diluted EPS: ₹0.71 (vs ₹0.08 in H1 FY2025)

Key Financial Performance - Consolidated (All amounts in ₹ Lakhs)

Quarterly Performance (Q2 FY2026):

  • Revenue from Operations: ₹4,420.38
  • Total Income: ₹4,477.58
  • Profit Before Tax: ₹1,782.80
  • Net Profit: ₹1,271.19
  • Basic EPS: ₹0.29
  • Diluted EPS: ₹0.29

Half-Yearly Performance (H1 FY2026):

  • Revenue from Operations: ₹6,772.61
  • Total Income: ₹6,883.78
  • Profit Before Tax: ₹3,600.02
  • Net Profit: ₹2,567.04
  • Basic EPS: ₹0.58
  • Diluted EPS: ₹0.58

Segment Performance Analysis

The company operates in two segments:

1. Pharmaceutical Segment

2. MedTech Segment (effective from October 1, 2025)

Q2 FY2026 Segment Revenue:

  • Pharmaceutical: ₹3,226.93
  • MedTech: ₹1,250.65
  • Total: ₹4,477.58

H1 FY2026 Segment Revenue:

  • Pharmaceutical: ₹5,633.13
  • MedTech: ₹1,250.65
  • Total: ₹6,883.78

Capital Structure Changes

  • Paid-up Equity Share Capital increased from ₹4,378.79 lakh (March 31, 2026) to ₹4,407.87 lakh (September 30, 2026)
  • During H1 FY2026, the company converted convertible warrants issued on preferential basis in earlier period into equity shares
  • Face value per share remains ₹1.00

Cash Flow Statement - Standalone

H1 FY2026:

  • Cash from Operating Activities: ₹149.35
  • Cash used in Investing Activities: ₹(1,537.74)
  • Cash from Financing Activities: ₹1,890.69
  • Net increase in Cash: ₹502.30
  • Cash & Cash Equivalents at period end: ₹1,093.93

Balance Sheet Position - Standalone (as of September 30, 2026)

  • Total Assets: ₹17,825.33 lakh
  • Total Equity: ₹12,391.36 lakh
  • Total Liabilities: ₹5,433.97 lakh
  • Cash & Cash Equivalents: ₹1,093.93 lakh

Corporate Developments

1. Company Name Change: Effective October 12, 2026, changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited

2. Warrant Conversion: Converted preferential warrants to equity shares during H1 FY2026

3. Segment Expansion: MedTech segment became operational from October 1, 2025

Subsidiary Information

The consolidated results include 8 subsidiaries with minimal financial impact:

  • Total assets (before consolidation): ₹37.20 lakh
  • Total revenue: ₹0
  • Total net loss: ₹(329.99) lakh for Q2 and ₹(537.13) lakh for H1
  • Subsidiaries considered not material to the Group

Auditor's Review

Shah Sanghvi & Associates issued unmodified review conclusions on both standalone and consolidated financial results, stating nothing came to their attention suggesting material misstatement.